A Phase 3 trial evaluating nivolumab in combination with chemotherapy for newly diagnosed Stage III-IV classic Hodgkin lymphoma reached primary completion on March 31, 2024. The study reported a statistically significant finding for progression-free survival (PFS) with a p-value of 0.005 in its primary analysis.
Background
This study investigated the use of immunotherapy drugs, nivolumab or brentuximab vedotin, alongside combination chemotherapy in patients with newly diagnosed Stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, aims to help the body's immune system target cancer cells. Brentuximab vedotin is a monoclonal antibody linked to a toxic agent, designed to deliver the agent directly to cancer cells.
Trial design
The Phase 3 study (NCT03907488) enrolled 994 participants with newly diagnosed Ann Arbor Stage III or IV classic Hodgkin lymphoma, including lymphocyte-depleted, mixed cellularity, and nodular sclerosis subtypes. The trial compared two arms: Arm I, which included chemotherapy, nivolumab, and radiation, against Arm II, which included chemotherapy, brentuximab vedotin, and radiation. Interventions included brentuximab vedotin, dacarbazine, doxorubicin hydrochloride, filgrastim, and nivolumab.
Key results
The trial reported key measurements for several outcomes:
- For Progression Free Survival (PFS): 41 participants in Arm I (Chemotherapy, Nivolumab, Radiation) experienced PFS events, compared to 81 participants in Arm II (Chemotherapy, Brentuximab Vedotin, Radiation).
- For Overall Survival (OS): 7 participants in Arm I experienced OS events, compared to 14 participants in Arm II.
- For Event-free Survival (EFS): 52 participants in Arm I experienced EFS events, compared to 91 participants in Arm II.
- For adverse events, various counts of participants were reported for each arm. In Arm I (Chemotherapy, Nivolumab, Radiation), these counts included 1 participant, 61 participants, and 2 participants. In Arm II (Chemotherapy, Brentuximab Vedotin, Radiation), the reported counts were 3 participants, 110 participants, and 3 participants.
The primary analysis of PFS used a stratified log rank test, yielding a statistically significant p-value of 0.005. Stratified Cox regression was used to estimate treatment hazard ratios, and the Kaplan-Meier method was used to estimate PFS curves.
What this means
The primary completion of this Phase 3 trial, coupled with the statistically significant p-value of 0.005 for progression-free survival, suggests a positive outcome for the nivolumab-containing regimen compared to the brentuximab vedotin-containing regimen in patients with newly diagnosed Stage III-IV classic Hodgkin lymphoma. The lower number of participants experiencing PFS, OS, and EFS events in the nivolumab arm indicates a potential clinical benefit. While adverse event counts were reported for both arms, the data does not provide details on the nature or severity of these events, limiting the ability to draw comprehensive safety conclusions from these specific numbers alone.
Source
The information regarding this trial's primary completion and results was obtained from ClinicalTrials.gov, a public database of clinical studies. The data for study NCT03907488, titled "Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma", was posted on March 31, 2024 on clinicaltrials.gov.